Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST): Prospective COVID-19 Natural History Study

Heart Disease Clinical Trial

Official title:

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African Americans Study (GENEFORECAST): Prospective COVID-19 Natural History Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05484882
• Other study ID #: 10000577
• Secondary ID: 000577-HG
• Status: Completed
• Start date: February 18, 2023
• Est. completion date: June 26, 2023

Study information

• Verified date: April 15, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background: The COVID-19 pandemic infected and killed African Americans at higher rates than other Americans. Researchers want to understand why. Objective: This natural history study will look at how genetic, environmental, and social factors may predict or affect COVID-19 in African Americans. Information from this study will be combined with data from the GENE-FORECAST study. Eligibility: African Americans who were previously enrolled in GENE-FORECAST. Design: The study includes a telephone interview and 1 visit to the NIH clinic. Participants may engage in either one or both of these activities. The telephone interview will last 20 minutes. Participants will talk about their experiences during the COVID-19 pandemic. The clinic visit will last up to 4 hours. Participants will have a physical exam. They will have blood and urine tests. They will be tested for COVID-19. A long swab will be inserted into a nostril to get a fluid sample from the back of the nose. They will have noninvasive tests of their blood vessels. One device used is a pen-like probe placed lightly on the wrist. Another is a rubber sleeve placed around a finger while a blood pressure cuff is used on the arm. Participants will have a test to measure the electrical activity in their heart. Stickers attached to wires will be placed on their chest, arms, and legs. Participants will answer more questions about COVID-19. They will talk about their health behavior. They will talk about their family's health and the neighborhood they live in. Other questions will ask how they feel, live, work, and play.

Description:

STUDY DESCRIPTION The objective is to conduct a prospective natural history study of Coronavirus disease 2019 (COVID-19) among a community-based cohort of African Americans enrolled in GENE-FORECAST for whom we have comprehensive psychosocial, clinical, and genetic data collected at baseline. Participants will be invited to take part in a 20-minute computer-assisted telephone interview (CATI) on exposures, attitudes and circumstances during the COVID-19 pandemic and to undergo a clinic visit for a physical exam, vascular function tests and biospecimen collection. We will identify social, clinical and genetic risk factors for COVID-19 and examine the interplay between social determinants of health and personal risk profiles to better understand the disparate burden of COVID-19 in the African American community. It is hypothesized that exposure to the SARS-CoV-2 virus and the development of COVID-19 will be associated with social and neighborhood factors, and that SARS-CoV-2 infection will adversely affect vascular function. OBJECTIVES Primary Objectives: 1. Define the effect of social factors (e.g., socio-economic status; neighborhood characteristics) on exposure to SARS-CoV-2 and the development of COVID-19. 2. Define the effect of SARS-CoV-2 infection and the development of COVID-19 on vascular function (e.g., pulse wave velocity). 3. Examine how social factors influence the effect of SARS-CoV-2 and COVID-19 on vascular function. Secondary Objectives: 1. Examine the effects of SARS-CoV-2 infection and COVID-19 on epigenome (whole-blood), transcriptome, (whole-blood, plasma microvesicles, urine), peripheral blood mononuclear cell (PBMC) single-cell RNA-seq, biomarker profile (e.g., CRP; d-dimer), cardiac function (EKG) and leukocyte telomere length. 2. Examine how social factors influence the effect of SARS-CoV-2 infection and COVID-19 on transcriptome and epigenome. ENDPOINTS Primary Endpoints: SARS-CoV-2 infection Vascular function (e.g., pulse wave velocity; vascular stiffness indices; reactive hyperemia) Secondary Endpoints: Transcriptome (whole-blood, plasma microvesicles, urine) Epigenome (whole-blood) PBMC single-cell RNA-seq Leukocyte telomere length Electrocardiogram (EKG) Biomarker profile (CRP, D-Dimer, ACE-2, HS-Troponin)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 431
• Est. completion date: June 26, 2023
• Est. primary completion date: June 26, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years and older

Eligibility

• INCLUSION CRITERIA In order to be eligible to participate in this study, an individual must meet all of the

following criteria:

• Self-identified African American men and women who previously enrolled in GENE-FORECAST, completed baseline activities and gave permission for recontact through the GENE-FORECAST protocol.
• Stated willingness to participate in study procedures.
• Ability of subject to understand and the willingness to give verbal informed consent for the CATI and the ability to understand and the willingness to sign a written informed consent document for the clinic visit. Individuals eligible for this protocol are previous GENE-FORECAST participants, all of whom are English speakers. Therefore, by default, this study includes only English speakers. EXCLUSION CRITERIA Only individuals who completed the baseline protocol of GENE-FORECAST and gave permission for recontact through the GENE-FORECAST protocol will be invited to participate. Among this group, there are no exclusions for this study except those who are pregnant.

Related Conditions & MeSH terms

• Cardiovascular Diseases
• COVID-19
• Heart Disease
• Heart Diseases

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland
United States	Westat, Inc.	Rockville	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Human Genome Research Institute (NHGRI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Define the effect of SARS-CoV-2 infection and the development of COVID-19 on vascular function (e.g., pulse wave velocity).	Vascular function (e.g., pulse wave velocity; vascular stiffness indices; reactive hyperemia)	48 month
Primary	Examine how social factors influence the effect of SARS-CoV-2 and COVID-19 on vascular function.	African Americans are disproportionately affected by SARS-CoV-2 infection and COVID-19. There are well-documented socioeconomic inequalities that contribute to this increased vulnerability. The disparate burden of disease demands a multidimensional approach informed by social determinants of health, geography (neighborhood), and personalized risk profiles. Among the social, environmental, clinical and genetic factors likely to be important for COVID-19 risks and outcomes, there is little understanding of the relative importance of these factors among African Americans and how they interact to affect morbidity and mortality.	48 month
Primary	Define the effect of social factors (e.g., socio-economic status; neighborhood characteristics) on exposure to SARS-CoV-2 and the development of COVID-19	Vascular function (e.g., pulse wave velocity; vascular stiffness indices; reactive hyperemia)	48 month
Secondary	Examine how social factors influence the effect of SARS-CoV-2 infection and COVID-19 on transcriptome and epigenome.	Biomarker profile (CRP, D-Dimer, ACE-2, HS-Troponin) * Analyses of all of the above endpoints will use change in values from baseline GENE-FORECAST to current measures.	48 month
Secondary	Examine the effects of SARS-CoV-2 infection and COVID-19 on epigenome (whole-blood), transcriptome, (whole-blood, plasma microvesicles, urine), peripheral blood mononuclear cell (PBMC) single-cell RNA-seq, biomarker profile (e.g., CRP; d-dimer),...	Transcriptome (whole-blood, plasma microvesicles, urine) Epigenome (whole-blood) PBMC single-cell RNA-seq Leukocyte telomere length	48 month

External Links

•   NIH Clinical Center Detailed Web Page